肝癌是一种常见的恶性肿瘤,严重危害人民健康。基于权威临床指南的公认证据与应用价值以及全球范围具有代表性指南各自的背景、相关研究状况和认知等因素存在的异同,有必要对其进行比较分析。美国肝病研究学会(American Association for...肝癌是一种常见的恶性肿瘤,严重危害人民健康。基于权威临床指南的公认证据与应用价值以及全球范围具有代表性指南各自的背景、相关研究状况和认知等因素存在的异同,有必要对其进行比较分析。美国肝病研究学会(American Association for the Study of Liver Diseases,AASLD)指南、欧洲肝脏研究学会(European Association for the Study of the Liver,EASL)指南、日本肝病学会(Japan Society of Hepatology,JSH)指南以及我国诊疗规范是全球范围分别具有代表性及影响力的肝癌诊疗指南。这四者在肝癌的诊疗上存在着一些共同和不同之处,拟对AASLD、ESAL、JSH指南以及我国诊疗规范从肝癌的分期、筛查与监测、诊断、治疗四个方面进行对比分析解读,从而对我国的肝癌规范化诊治起到一些指导作用。展开更多
Hepatitis B virus （HBV） infection causes a tremendous clinical burden across the world with more than half a million people dying annually from HBV related disease. Significant advances have been made in HBV treatme...Hepatitis B virus （HBV） infection causes a tremendous clinical burden across the world with more than half a million people dying annually from HBV related disease. Significant advances have been made in HBV treatment in the past decade and several guidelines have been published by professional societies and expert panels. Although these recommendations have been valuable to help optimize HBV treatment, there is discordance in treatment criteria and many patients infected with HBV may fall outside of these recommendations. This paper systematically reviews the natural history of the disease and compares and contrasts the recommendations for initiation of treatment from the various societies. There is also discussion of special groups that require particular consideration and some of the open research questions and future research directions within the field.展开更多
文摘肝癌是一种常见的恶性肿瘤,严重危害人民健康。基于权威临床指南的公认证据与应用价值以及全球范围具有代表性指南各自的背景、相关研究状况和认知等因素存在的异同,有必要对其进行比较分析。美国肝病研究学会(American Association for the Study of Liver Diseases,AASLD)指南、欧洲肝脏研究学会(European Association for the Study of the Liver,EASL)指南、日本肝病学会(Japan Society of Hepatology,JSH)指南以及我国诊疗规范是全球范围分别具有代表性及影响力的肝癌诊疗指南。这四者在肝癌的诊疗上存在着一些共同和不同之处,拟对AASLD、ESAL、JSH指南以及我国诊疗规范从肝癌的分期、筛查与监测、诊断、治疗四个方面进行对比分析解读,从而对我国的肝癌规范化诊治起到一些指导作用。
文摘Hepatitis B virus （HBV） infection causes a tremendous clinical burden across the world with more than half a million people dying annually from HBV related disease. Significant advances have been made in HBV treatment in the past decade and several guidelines have been published by professional societies and expert panels. Although these recommendations have been valuable to help optimize HBV treatment, there is discordance in treatment criteria and many patients infected with HBV may fall outside of these recommendations. This paper systematically reviews the natural history of the disease and compares and contrasts the recommendations for initiation of treatment from the various societies. There is also discussion of special groups that require particular consideration and some of the open research questions and future research directions within the field.
